Sabrawishy hospital,Dokki,Giza,Egypt Report issue

Academic/Hospital

Organization Overview

First Clinical Trial
2020
NCT04383548
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sabrawishy hospital,Dokki,Giza,Egypt

Active Ingredients

Drugs in Other Trials (1)

COVID-19 convalescent plasma (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1